US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

iShares Neuroscience and Healthcare ETF

32.55

-0.3131-0.95%

Post-market: 32.55-0.0070-0.02%17:07 EDT

Volume:432

Turnover:14.10K

Market Cap:6.51M

PE:- -

High:32.56

Open:32.56

Low:32.55

Close:32.87

52wk High:43.01

52wk Low:27.40

Shares:200.00K

Float Shares:200.00K

Volume Ratio:0.31

T/O Rate:0.22%

Dividend:0.32

Dividend Rate:0.98%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell

MT Newswires Live

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)

Scholar Rock announces FDA approval of isembyld

FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy Patients Aged 2 and Older on SMN2 Therapy

Scholar Rock Holding Corporation - Isembyld U.S. Commercial Launch Underway; Product Available to Ship in Coming Days

THOMSON REUTERS

Scholar Rock Announces FDA Approval of Isembyld™ (Apitegromab-Mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (Sma)

THOMSON REUTERS

US FDA Approves Scholar Rock's Muscle Weakness Drug

US FDA - Approves Isembyld for Spinal Muscular Atrophy in Patients Aged 2 Years and Older

THOMSON REUTERS

Scholar Rock Holdings trading halted, news pending

NASDAQ Trade Halt Halt News Pending at 05:07 Pm

Dianthus Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Price Target $135

THOMSON REUTERS

Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.

Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program

THOMSON REUTERS

Structure weakness ‘disconnected’ from underlying data, says Jefferies

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

Scholar Rock Holding Price Target Maintained with a $65.00/Share by HC Wainwright & Co.

Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder

Mizuho survey shows no consensus into Alkermes ADHD data

Dianthus Therapeutics Inc : Citigroup Initiates Coverage with Buy Rating; Target Price $156

THOMSON REUTERS

Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/IBRN/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBRN","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","market":"US","secType":"STK","nameCN":"iShares Neuroscience and Healthcare ETF","latestPrice":32.552,"timestamp":1790971200000,"preClose":32.8651,"halted":0,"volume":432,"hourTrading":{"tag":"盘后","latestPrice":32.545,"preClose":32.552,"latestTime":"17:07 EDT","volume":10,"amount":323.738,"timestamp":1790975268525,"change":-0.007,"changeRate":-0.000215,"amplitude":0},"delay":0,"changeRate":-0.00952682328670835,"floatShares":200000,"shares":200000,"eps":0,"marketStatus":"Market Closed","change":-0.3131,"latestTime":"10-02 16:00:00 EDT","open":32.561,"high":32.561,"low":32.545,"amount":14103,"amplitude":0.000487,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"exchange":"ARCA","adjPreClose":32.8651,"sharesOutstanding":150000,"nav":32.771593,"aum":6554318.6,"dividendRate":0.00979,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":32.545,"preClose":32.552,"latestTime":"17:07 EDT","volume":10,"amount":323.738,"timestamp":1790975268525,"change":-0.007,"changeRate":-0.000215,"amplitude":0},"volumeRatio":0.3104039106268791,"impliedVol":0.0726,"impliedVolPercentile":0.3187},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBRN\",,,,,undefined,":{"symbol":"IBRN","floatShares":200000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3104039106268791,"shares":200000,"dividePrice":0.3187,"high":32.561,"amplitude":0.000487,"preClose":32.8651,"low":32.545,"week52Low":27.4025,"pbRate":"--","week52High":43.01,"institutionHeld":0,"latestPrice":32.552,"eps":0,"divideRate":0.00979,"volume":432,"delay":0,"ttmEps":0,"open":32.561,"prevYearClose":32.3193,"prevWeekClose":33.3342,"prevMonthClose":33.265,"prevQuarterClose":33.265,"fiveDayClose":33.3342,"twentyDayClose":39.3744,"sixtyDayClose":40.2891},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBRN\",params:#limit:5,,,undefined,":[{"date":"2025-12-16","symbol":"IBRN","amount":0.319807,"announcedDate":"2025-12-15","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-16","defaultRemindTime":1765895400000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-19","payableDate":"2025-12-16","currency":"USD","dateTimestamp":1765861200000,"payDate":"2025-12-19"},{"date":"2024-12-17","symbol":"IBRN","amount":0.10114,"announcedDate":"2024-12-16","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"iShares Neuroscience and Healthcare ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-20","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-20"},{"date":"2023-12-20","symbol":"IBRN","amount":0.006303,"announcedDate":"2023-12-19","type":"dividend","market":"US","newRecordDate":"2023-12-21","defaultRemindTime":1703082600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-12-27","payableDate":"2023-12-21","currency":"USD","dateTimestamp":1703048400000,"payDate":"2023-12-27"},{"date":"2023-06-07","symbol":"IBRN","amount":0.008241,"announcedDate":"2023-05-12","type":"dividend","market":"US","newRecordDate":"2023-06-08","defaultRemindTime":1686144600000,"name":"iShares Neuroscience and Healthcare ETF","recordDate":"2023-06-13","payableDate":"2023-06-08","currency":"USD","dateTimestamp":1686110400000,"payDate":"2023-06-13"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBRN\",market:\"US\",,,undefined,":[{"executeDate":"2023-06-07","recordDate":"2023-06-08","paymentDate":"2023-06-13","value":0.008241,"currency":"USD"},{"executeDate":"2023-12-20","recordDate":"2023-12-21","paymentDate":"2023-12-27","value":0.006303,"currency":"USD"},{"executeDate":"2024-12-17","recordDate":"2024-12-17","paymentDate":"2024-12-20","value":0.10114,"currency":"USD"},{"executeDate":"2025-12-16","recordDate":"2025-12-16","paymentDate":"2025-12-19","value":0.319807,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBRN\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBRN\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667643659","title":"Scholar Rock Gets FDA Approval for Spinal Muscular Atrophy Treatment in Children, Adults; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2667643659","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667643659?lang=en_us&edition=fundamental","pubTime":"2026-09-14 16:30","pubTimestamp":1789374609,"startTime":"0","endTime":"0","summary":"Scholar Rock  has received US Food and Drug Administration approval for Isembyld to treat spinal muscular atrophy in certain patients aged two years and above, the company said Friday.Isembyld is expected to ship in the coming days, Scholar Rock said, adding that the company has received a rare pediatric disease priority review voucher that may be used to obtain priority review for a future marketing application.Spinal muscular atrophy is a severe neuromuscular disease that leads to an irreversible loss of motor neurons and progressive muscle wasting.Scholar Rock shares were up 8.6% in premarket activity Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IBRN","THNR","SRRK","BK4139","BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667639042","title":"Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), Scholar Rock Holding (SRRK) and Danaher (DHR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2667639042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667639042?lang=en_us&edition=fundamental","pubTime":"2026-09-14 09:30","pubTimestamp":1789349409,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Summit Therapeutics (SMMT), Scholar Rock Holding (SR...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-scholar-rock-holding-srrk-and-danaher-dhr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-summit-therapeutics-smmt-scholar-rock-holding-srrk-and-danaher-dhr-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2211814178.USD","LU0943347566.SGD","LU2063271972.USD","LU2125910336.SGD","LU2112291526.USD","IE00BQXX3F31.USD","LABU","HCSG","DHR","LU0109391861.USD","LU2125909593.SGD","BK4585","BK4121","IE000M9KFDE8.USD","LU0820561818.USD","THNR","LU0708995401.HKD","LU0528227936.USD","IBRN","LU1057294990.SGD","IE00BQXX3D17.EUR","FMED","LU0289739343.SGD","LU0312595415.SGD","SGXZ57979304.SGD","LU0289960550.SGD","LU0114720955.EUR","LU0320765059.SGD","SMMT","BK4581","LU0820562030.AUD","LU1061106388.HKD","LU1791710582.SGD","LU1804176565.USD","LU2023250504.SGD","XBI","LU1267930730.SGD","LU0511384066.AUD","BK4534","BK4588","LU2265009873.SGD","LU0097036916.USD","LU1923621640.USD","LU0187121727.USD","SRRK","IE00BKVL7J92.USD","LU2125909247.SGD","XLV","LU0029874061.USD","LU1974910355.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666577803","title":"Scholar Rock announces FDA approval of isembyld","url":"https://stock-news.laohu8.com/highlight/detail?id=2666577803","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666577803?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:30","pubTimestamp":1789165818,"startTime":"0","endTime":"0","summary":"Scholar Rock (SRRK) announced that the FDA has approved isembyld for the treatment of spinal muscular atrophy in adults and children two years of a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-announces-fda-approval-of-isembyld-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IBRN","IBB","LABU","IDNA","RSPH","TECB","SRRK","IYH","MRNY","BK4585","NVIB","BMED","FRTY","BBP","XLVX","TBXU","THNR","MRNX","BK4588","PINK","LFSC","PSCH","SYNB","MEDI","GNMX","IEIH","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666572057","title":"FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy Patients Aged 2 and Older on SMN2 Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2666572057","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666572057?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:25","pubTimestamp":1789165519,"startTime":"0","endTime":"0","summary":"FDA approves Scholar Rock’s ISEMBYLD for spinal muscular atrophy patients aged 2 and older on SMN2 therapyFDA cleared Scholar Rock’s ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy in adults, ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL2vCy1g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","BK4139","SRRK","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666957270","title":"Scholar Rock Holding Corporation - Isembyld U.S. Commercial Launch Underway; Product Available to Ship in Coming Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2666957270","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666957270?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:25","pubTimestamp":1789165500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA1TJGD4:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRRK","THNR","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666706572","title":"Scholar Rock Announces FDA Approval of Isembyld™ (Apitegromab-Mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (Sma)","url":"https://stock-news.laohu8.com/highlight/detail?id=2666706572","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666706572?lang=en_us&edition=fundamental","pubTime":"2026-09-12 06:25","pubTimestamp":1789165500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nTUA1TJGD4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SRRK","BK4139","THNR","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666572586","title":"US FDA Approves Scholar Rock's Muscle Weakness Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2666572586","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666572586?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:24","pubTimestamp":1789161898,"startTime":"0","endTime":"0","summary":"US FDA approves Scholar Rock's muscle weakness drugSept 11 (Reuters)-The U.S. Food and Drug Administration on Friday approved Scholar Rock'sSRRK.Otherapy to treat a rare genetic condition that causes muscle weakness.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nL4N4531I3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIIB","BMED","THNR","LU0234570918.USD","IBRN","PBE","BK4585","IE00B894F039.SGD","BK4533","BK4588","SRRK","LU0109394709.USD","LU0889565916.HKD","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","LU0320765992.SGD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666357232","title":"US FDA - Approves Isembyld for Spinal Muscular Atrophy in Patients Aged 2 Years and Older","url":"https://stock-news.laohu8.com/highlight/detail?id=2666357232","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666357232?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:22","pubTimestamp":1789161732,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530QK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["THNR","SRRK","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666343572","title":"Scholar Rock Holdings trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2666343572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666343572?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:10","pubTimestamp":1789161018,"startTime":"0","endTime":"0","summary":"17:07 EDT Scholar Rock (SRRK) Holdings trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-holdings-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-holdings-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IBRN","THNR","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666857403","title":"NASDAQ Trade Halt Halt News Pending at 05:07 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2666857403","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666857403?lang=en_us&edition=fundamental","pubTime":"2026-09-12 05:07","pubTimestamp":1789160857,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 05:07 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nAQN2MJ0M9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","SRRK","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666254398","title":"Dianthus Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Price Target $135","url":"https://stock-news.laohu8.com/highlight/detail?id=2666254398","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666254398?lang=en_us&edition=fundamental","pubTime":"2026-09-11 12:34","pubTimestamp":1789101255,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4520M0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DNTH","BK4139","IBRN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666590103","title":"Biohaven Stock is Sinking. Epilepsy Drug Trial Roadblock is Only the Latest Blow.","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590103","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666590103?lang=en_us&edition=fundamental","pubTime":"2026-09-11 02:14","pubTimestamp":1789064040,"startTime":"0","endTime":"0","summary":"Biohaven has hit another regulatory hurdle for its epilepsy candidate opakalim, piling fresh uncertainty onto the cash-strapped biotech.Biohaven confirmed Thursday that the Food and Drug Administratio","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","XENE","BK4139","LU1093756168.USD","BHVN","IBRN","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666567022","title":"Alkermes Announces Launch of 9TH Annual Alkermes Pathways Research Awards® Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2666567022","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666567022?lang=en_us&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUA8WKBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","FBT","MEDX","PSIL","PSCH","IBRN","ALKS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666377632","title":"Structure weakness ‘disconnected’ from underlying data, says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2666377632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666377632?lang=en_us&edition=fundamental","pubTime":"2026-09-09 04:00","pubTimestamp":1788897615,"startTime":"0","endTime":"0","summary":"After Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates, ACCG-2671 and aleniglipron, Jefferies see...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-weakness-disconnected-from-underlying-data-says-jefferies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GSKH","PBPH","CNCR","APXH","IBRN","LLYX","WDNA","GDOC","FHLC","MDTX","PSCH","SYNB","PSIL","XPH","HYLG","BBH","PBE","FBT","SBIO","PTH","HRTS","PINK","GNOM","BME","CANC","GPCR","MRNY","NVIB","BIB","CURE","LFSC","MEDX","JHMH","PJP","IEIH","SURI","IBB","TBXU","IBBQ","FXH","AZNH","MNTL","IDNA","RSPH","GNMX","IBBJ","MEDI","JDOC","FTXH","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665637847","title":"Structure Therapeutics reports ACCG-2671, aleniglipron trial results","url":"https://stock-news.laohu8.com/highlight/detail?id=2665637847","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665637847?lang=en_us&edition=fundamental","pubTime":"2026-09-08 20:36","pubTimestamp":1788871007,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) reported clinical trial results from its two lead product candidates: ACCG-2671, an oral, non-peptide, small molecule...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/structure-therapeutics-reports-accg-2671-aleniglipron-trial-results-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBXU","IBRN","GNOM","IDNA","NVIB","SYNB","JHMH","BBP","PSIL","PSCH","RSPH","GDOC","MDTX","FTXH","MEDX","PINK","GNMX","LENZ","PTH","CANC","SURI","AZNH","IBBJ","APXH","PBE","IBBQ","FHLC","MRNY","PJP","BIB","FBT","HYLG","XPH","MNTL","CNCR","HRTS","JDOC","FXH","MEDI","GPCR","BBH","CURE","GSKH","LLYX","PBPH","SBIO","WDNA","IBB","BME","LFSC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665322621","title":"Scholar Rock Holding Price Target Maintained with a $65.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2665322621","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665322621?lang=en_us&edition=fundamental","pubTime":"2026-09-08 19:00","pubTimestamp":1788865200,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/SRRK/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["THNR","IBRN","SRRK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121796426","title":"Brain-Computer Interface Startups Must Walk the Line Between Vast Potential and Near-Term Medical Reality, Says Formatia Founder","url":"https://stock-news.laohu8.com/highlight/detail?id=1121796426","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121796426?lang=en_us&edition=fundamental","pubTime":"2026-09-05 14:10","pubTimestamp":1788588618,"startTime":"0","endTime":"0","summary":"At the 2026 Yabuli Forum Summer Annual Meeting, held September 4-6 in Chengdu, Sichuan, under the theme \"Enterprise Innovation and Cycle Crossing,\" Formatia Founder and CEO Peng Lei offered a...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDEV","09996","BK1583","GDOC","MNTL","RSPH","PTH","LGHT","BK1574","IEIH","IBRN","HART","LNGR","MEDX","AGNG","BK1100","159883"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665735956","title":"Mizuho survey shows no consensus into Alkermes ADHD data","url":"https://stock-news.laohu8.com/highlight/detail?id=2665735956","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665735956?lang=en_us&edition=fundamental","pubTime":"2026-09-05 03:35","pubTimestamp":1788550508,"startTime":"0","endTime":"0","summary":"Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mizuho-survey-shows-no-consensus-into-alkermes-adhd-data-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ALKS","PSIL","ADHD","ABVC","MEDX","BK4139","PSCH","IBRN","FBT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664335196","title":"Dianthus Therapeutics Inc : Citigroup Initiates Coverage with Buy Rating; Target Price $156","url":"https://stock-news.laohu8.com/highlight/detail?id=2664335196","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664335196?lang=en_us&edition=fundamental","pubTime":"2026-09-04 18:09","pubTimestamp":1788516590,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nFWN44W0N3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IBRN","DNTH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664802637","title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2664802637","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664802637?lang=en_us&edition=fundamental","pubTime":"2026-09-04 06:33","pubTimestamp":1788474793,"startTime":"0","endTime":"0","summary":"Alkermes EVP, CLO David Joseph Gaffin disposes of 2,034 common shares worth $97,651.34Alkermes EVP and chief legal officer David Joseph Gaffin sold 2,034 ordinary shares on Sep. 3, 2026 at USD 48.01.D","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260903:nNDL5DSLJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Alkermes EVP, CLO David Joseph Gaffin Disposes of 2,034 Common Shares Worth $97,651.34","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FBT","IBRN","MEDX","ALKS","PSIL","BK4139","PSCH"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":6,"totalSize":200,"code":"91000000","status":"200"}]}}